


SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME	ORPHENADRINE CITRATE, USP
PRODUCT CODE	0452
SUPPLIER	MEDISCA Inc. Tel.: 1.800.932.1039 Fax.: 1.855.850.5855 626 Tom Miller Road, Plattsburgh, NY, 12901 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020
EMERGENCY PHONE	CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 National Chemical Emergency Centre 44(0)1235239670
RECOMMENDED USES	Pharmaceutical Manufacturing
RESTRICTIONS ON USE	Not applicable

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION	Acute Toxicity - Oral (Category 3) Specific Target Organ Toxicity - Single Exposure (Category 3) - Narcotic effects	
PICTOGRAM		
SIGNAL WORD	Warning	
HAZARD STATEMENT(S)	Toxic if swallowed. May cause drowsiness or dizziness.	
ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS	Not Applicable.	
PRECAUTIONARY STATEMENT(S)	Prevention	Wash thoroughly after handling. Do not eat, drink or smoke when using this product. Wear protective gloves, protective clothing, eye protection, face protection. Avoid breathing dust/fume/gas/mist/vapors/spray Use only outdoors or in a well-ventilated area
	Response	IF SWALLOWED: Immediately call a poison center. Get emergency medical help immediately. Rinse mouth. IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a poison center or doctor. Get medical help if you feel unwell.

Storage Store in a well-ventilated place.
Keep container tightly closed.
Store locked up.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations

HMIS CLASSIFICATION

Health Hazard	2	Flammability	0
Reactivity	0	Personal Protection	E

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME	Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-, (±)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1).								
BOTANICAL NAME	Not applicable								
SYNONYM	Mephenamine citrate								
CHEMICAL FORMULA	C ₁₈ H ₂₃ NO·C ₆ H ₈ O ₇								
CHEMICAL FAMILY	Ethanolamine derivative. Muscarinic receptor antagonist.								
CAS NUMBER	4682-36-4								
ALTERNATE CAS NUMBER	Not applicable								
MOLECULAR WEIGHT	461.50								
COMPOSITION	<table border="1"> <thead> <tr> <th>CHEMICAL NAME</th> <th>CAS NUMBER</th> <th>EC NUMBER</th> <th>% BY WEIGHT</th> </tr> </thead> <tbody> <tr> <td>ORPHENADRINE CITRATE</td> <td>4682-36-4</td> <td>225-137-5</td> <td>100</td> </tr> </tbody> </table>	CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT	ORPHENADRINE CITRATE	4682-36-4	225-137-5	100
CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT						
ORPHENADRINE CITRATE	4682-36-4	225-137-5	100						

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

NOTES Orphenadrine is a tertiary amine antimuscarinic. Muscarinic receptor antagonists (MRA) are a type of anticholinergic agent that block the activity of muscarinic acetylcholine receptors.

SECTION 4: FIRST-AID MEASURES

IN CASE OF EYE CONTACT Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid.

IN CASE OF SKIN CONTACT Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician

MEDICAL ATTENTION AND SPECIAL TREATMENT Get emergency medical help.

SYMPTOMS CAUSED BY EXPOSURE Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM THE CHEMICAL

Not applicable

FLAMMABLE PROPERTIES

May be combustible at high temperature

HAZARDOUS COMBUSTION PRODUCTS

Under fire conditions, hazardous fumes will be present.

SUITABLE & UNSUITABLE EXTINGUISHING MEDIA

Small fire: dry chemical, CO₂ or water spray. **Large fire:** dry chemical, CO₂, alcohol resistant foam or water spray. Do not get water inside containers.

PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

SECTION 6: ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR CONTAINMENT

On land, sweep or shovel into suitable containers. Minimize generation of dust.

CLEANUP PROCEDURE

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONS

See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING

Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE

Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

STORAGE CONDITIONS

Store in original container, tightly sealed, protected from direct sunlight and moisture.

Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40°C are acceptable.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: ORPHENADRINE CITRATE CAS #: 4682-36-4

	Country	Limit value-8 hours		Limit value-Short Term		IDLH	REL	Advisory	Notes
		ppm	mg/m ³	ppm	mg/m ³				

OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSIS	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSE	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
GESTIS	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed ; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

EXPOSURE GUIDELINES

Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m³

PERSONAL PROTECTIVE EQUIPMENT

Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. **Skin:** Wear appropriate gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. **Thermal Hazards:** For products representing a thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS

Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

BIOLOGICAL MONITORING

Not available

CONTROL BANDING

Not available

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

Solid

DESCRIPTION

White, practically odorless, crystalline powder.

SOLUBILITY

Sparingly soluble in water; slightly soluble in alcohol; insoluble in chloroform, in benzene, and in ether.

ODOR

Odorless or Practically odorless

FLAMMABILITY

May be combustibile at high temperature

AUTO-IGNITION TEMPERATURE

Not available

BOILING POINT

Not available

DECOMPOSITION TEMPERATURE

Not available

EVAPORATION RATE

Not available

EXPLOSIVE LIMIT

Not available

FLASH POINT

Not available

log P (OCTANOL-WATER)

Not available

LOWER FLAMMABLE/EXPLOSIVE LIMIT(S)

Not available

MELTING/FREEZING POINT

(134 - 138)°C,
(273.2-280.4)°F

PARTICLE CHARACTERISTICS

Not available

OXIDIZING PROPERTY

Not available

pH

3.7 (1%)

RELATIVE DENSITY (WATER = 1)	Not available	SPECIFIC GRAVITY	Not available	UPPER FLAMMABLE/EXPLOSIVE LIMIT(S)	Not available
VAPOR DENSITY (AIR = 1)	Not available	VAPOR PRESSURE	Not available	VISCOSITY	Not available

The physical data presented above are typical values and should not be construed as a specification.

SECTION 10: STABILITY AND REACTIVITY

REACTIVITY	Not established
CHEMICAL STABILITY	Stable under recommended storage conditions
INCOMPATIBLE MATERIALS	Strong oxidants, acids and bases
HAZARDOUS DECOMPOSITION PRODUCTS	Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur
HAZARDOUS POLYMERIZATION	Will not occur
POSSIBILITY OF HAZARDOUS REACTION	Not established
CONDITIONS TO AVOID	Moisture, sunlight and extreme temperatures

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY	Oral: Rat: LD50: (mg/kg): 255 Dermal: Rabbit: LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): Not available
SKIN CORROSION/IRRITATION	Due to lack of data the classification is not possible.
SERIOUS EYE DAMAGE/EYE IRRITATION	Due to lack of data the classification is not possible.
RESPIRATORY SENSITIZATION	Due to lack of data the classification is not possible.
SKIN SENSITIZATION	Due to lack of data the classification is not possible.
GERM CELL MUTAGENICITY	Due to lack of data the classification is not possible.
CARCINOGENICITY	OSHA ORPHENADRINE CITRATE is not listed. NTP ORPHENADRINE CITRATE is not listed. IARC ORPHENADRINE CITRATE is not evaluated. California Proposition This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.
ADDITIONAL CARCINOGENICITY INFORMATION	Due to lack of data the classification is not possible.
REPRODUCTIVE TOXICITY	Due to lack of data the classification is not possible. In animal studies, a related material caused birth defects.
SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE	Narcotic effects: May cause drowsiness or dizziness.

**SPECIFIC TARGET ORGAN
TOXICITY - REPEATED
EXPOSURE
ASPIRATION HAZARDS
SIGNS AND SYMPTOMS OF
EXPOSURE**

Due to lack of data the classification is not possible.

Based on available data, the classification criteria are not met.

ROUTES OF EXPOSURE:

Oral, Dermal, Inhalation, Eye contact

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:

Not available

DELAYED HEALTH EFFECT FROM EXPOSURE:

Shock. Respiratory arrest.

Symptoms related to the physical, chemical, and toxicological characteristics:

Nausea. Vomiting. Decreased urination. Painful or difficult urination. Dry mouth. Changes in vision. Eye pain. Excitement. Agitation. Insomnia. Hallucinations. Drowsiness. Trembling. Headache. Dizziness. Fainting. Cramps. Constipation. Irregular heartbeat. Weak pulse. Shallow breathing. Pale skin. Bluish skin. Confusion. Sweating. Loss of consciousness. Seizures.

Medical conditions aggravated by exposure:

Porphyria. Active alcoholism. Heart problems. Urinary tract obstruction. Glaucoma. Myasthenia gravis. Stenosing peptic ulcer. Prostate enlargement. Gastrointestinal tract obstruction.

POTENTIAL HEALTH EFFECTS

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion Harmful if swallowed.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes May cause eye irritation.

SECTION 12: ECOLOGICAL INFORMATION

ECOTOXICITY

EC50: 48 Hr: Crustacea: (mg/L): Not available

LC50: 96 Hr: Fish: (mg/L): Not available

EC50: 72 or 96 Hr: Algae (or other aqua plants): (mg/L): Not available

**PERSISTENCE AND
DEGRADABILITY**

Not available.

BIOACCUMULATIVE POTENTIAL

Not available

MOBILITY IN SOIL

Not available

OTHER ADVERSE EFFECTS

Not available

This product is not intended to be released into the environment

SECTION 13: DISPOSAL CONSIDERATIONS

DISPOSAL METHODS

Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION

UN PROPER SHIPPING NAME

TOXIC SOLID, ORGANIC, N.O.S.

UN NUMBER

2811

CLASS	6.1
PACKING GROUP	III
AUSTRALIA	
HAZCHEM	2X
EU	
TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE	Not listed
ENVIRONMENTAL HAZARDS	Not available
SPECIAL SHIPPING INFORMATION	Not applicable

SECTION 15: REGULATORY INFORMATION

UNITED STATES REGULATIONS

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR	EPA 40 CFR Part 355 Appendix A	EPA 40 CFR Part 355 Appendix B	Pennsylvania	Right-to-know New Jersey	Massachusetts	California Prop 65
ORPHENADRINE CITRATE 4682-36-4	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemicals
ORPHENADRINE CITRATE 4682-36-4	N/L	Listed as Schedule 4*	N/L	Listed*	N/L	N/L

N/L = Not Listed

EU REGULATIONS

Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
ORPHENADRINE CITRATE 4682-36-4	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

SUBJECT TO INTERNATIONAL AGREEMENT Not applicable

NOTES *Listed as the base

SECTION 16: OTHER INFORMATION

REFERENCES

Available upon request

ABBREVIATIONS AND ACRONYMS

ACGIH - American Conference of Governmental Industrial Hygienists; **AIHA WEEL** – American Industrial Hygiene Association Workplace Environment Exposure Levels; **CAESAR** – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; **CAS** – Chemical Abstract Service; **CERCLA** – Comprehensive Environmental Response, Compensation, and Liability Act; **EC50** – Effective Concentration, 50%; **EPA** – Environmental Protection Agency; **GHS** – Global Harmonized System; **HMIS** – Hazardous Materials Information System; **HSE** – Health and Safety Executive; **HSIS** – Hazardous Substances Information System; **IARC** – International Agency for Research on Cancer; **IDLH** - Immediately Dangerous to Life or Health; **IRFMN** – Ready Biodegradability Model; **ISS** – Istituto Superiore Sanità; **LC50** – Lethal Concentration, 50%; **LD50** – Lethal Dose, 50%; **MSHA** - Mine Safety and Health Administration; **NIOSH** – National Institute for Occupational Safety and Health; **NTP** – National Toxicology Program; **OSHA PEL** – Occupational Safety & Health Administration Permissible Exposure Limits; **QSAR** – Quantitative Structure-activity relationship; **REL** - Recommended Exposure Limit; **SARA** – Superfund Amendments and Reauthorization Act; **STEL** – Short Term Exposure Limit; **TLV** – Threshold Limit Value; **TWA** – Time Weighted Average; **WHMIS** – Workplace Hazardous Materials Information System

LAST REVISION

07/2023

SUPERSEDES

05/2021

For a list of changes to the SDS since the last version, please communicate with MEDISCA at www.medisca.com

DISCLAIMER

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.